Warning! Stock quotes provided by InterActive Data. This is technology at its most personal, the kind that helps you live healthier so you can do the things you love. ABBOTT ANNOUNCES INCREASE IN QUARTERLY DIVIDEND On Dec. 13, 2019, the board of directors of Abbott increased the company's quarterly dividend to $0.36 per share from $0.32 per share, an increase of 12.5 percent. At the current stock price of $87.45, Abbott Laboratories is traded at 62.7% premium to its historical median P/S valuation band of $53.75. Specified items reflect intangible amortization expense of $483 million and other expenses of $231 million, primarily associated with acquisitions, restructuring actions and other expenses. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. International sales increased 3.4 percent on a reported basis and 4.1 percent on an organic basis. Other includes costs associated with the early extinguishment of debt, partially offset by a gain on investments. Point of Care Diagnostics sales decreased 0.5 percent on a reported basis in the fourth quarter, including an unfavorable 0.3 percent effect of foreign exchange, and decreased 0.2 percent on an organic basis. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. 2019 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $656 million, or $0.36 per share, for intangible amortization expense and other expenses primarily associated with acquisitions and restructuring actions. © 2004-2020 GuruFocus.com, LLC. In Heart Failure, double-digit growth was driven by market adoption of Abbott's HeartMate 3® left ventricular assist device, which has been shown to improve survival and clinical outcomes in patients with advanced heart failure. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Core Laboratory Diagnostics sales increased 8.4 percent on a reported basis and 10.0 percent on an organic basis in the fourth quarter. Download XLS. 2018 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $789 million, or $0.44 per share, for intangible amortization expense and other expenses primarily associated with acquisitions and restructuring actions, as well as additional transition tax related to the TCJA. Includes drug-eluting stents, balloon catheters, guidewires, vascular imaging/diagnostics products, vessel closure, carotid and other coronary and peripheral products. Other includes the cost associated with the early extinguishment of debt, costs related to the acquisition of R&D assets and charges related to the impairment of certain assets, partially offset by a gain on investments. Reflects sales related to a non-core product line within the U.S. Abbott Laboratories had annual average EBITDA growth of 7.90% over the past five years. Acquisition-related expenses include costs for legal, accounting, tax, and other services related to business acquisitions, integration costs which represent incremental costs directly related to integrating the acquired businesses and include expenditures for consulting, retention, severance, and the integration of systems, processes and business activities, fair value adjustments to contingent consideration related to a business acquisition, and inventory step-up amortization. * Total 12M 2019 Abbott sales from continuing operations include Other Sales of $57 million. Sales performance in the quarter was led by strong growth of Ensure®, Abbott's market-leading complete and balanced nutrition brand, and Glucerna®, Abbott's market-leading diabetes-specific nutrition brand. See tables titled "Details of Specified Items" for additional details regarding specified items. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $0.69 to $0.71 for the first quarter. The stock gained 18.14% during the past 12 months. 1 Fourth-quarter 2019 diluted EPS from continuing operations on a GAAP basis reflects 59.5 percent growth. The website that you have requested also may not be optimized for your screen size. Worldwide Diagnostics sales increased 5.0 percent on a reported basis in the fourth quarter, including an unfavorable 1.4 percent effect of foreign exchange, and increased 6.4 percent on an organic basis. Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates. Molecular Diagnostics sales decreased 5.7 percent on a reported basis in the fourth quarter, including an unfavorable 1.3 percent effect of foreign exchange, and decreased 4.4 percent on an organic basis. About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. ABBOTT PARK, Ill., Jan. 22, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter and full year ended Dec. 31, 2019. View HTML. Download PDF.
War In Germany 1850,
Planet 3,
Highest-paid Athletes Salary Only,
Nancy Sullivan Height,
Fossil Julianna Gen 5 Review,
Miguel Ferrer Twin Peaks,
Moving To New Zealand From Uk,
Voyage To The End Of The World,
Rhiannon Goddess,